Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
699.2 INR | -0.30% | -2.07% | -12.51% |
May. 01 | Rossari Biotech's Consolidated Profit Climbs in FIscal Q4 | MT |
Apr. 30 | Transcript : Rossari Biotech Limited, Q4 2024 Earnings Call, Apr 30, 2024 |
Strengths
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
- Analyst opinion has improved significantly over the past four months.
- Over the past twelve months, analysts' opinions have been strongly revised upwards.
- There is high visibility into the group's activities for the coming years. Outlooks on future revenues from analysts covering the equity remain similar. Such hardly dispersed estimates support highly predictable sales for the current and upcoming fiscal years.
- Analysts' price targets are all relatively close, reflecting good visibility on the company's valuation.
Weaknesses
- The firm trades with high earnings multiples: 29.17 times its 2024 earnings per share.
- The company appears highly valued given the size of its balance sheet.
- The company is not the most generous with respect to shareholders' compensation.
- The company's earnings releases usually do not meet expectations.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Specialty Chemicals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-12.51% | 464M | C+ | ||
+17.80% | 66.43B | A- | ||
+2.92% | 49.89B | A- | ||
+19.98% | 41.88B | B+ | ||
+20.88% | 26.48B | A- | ||
+12.04% | 19.68B | C+ | ||
+1.27% | 17B | B+ | ||
-22.98% | 16.12B | A- | ||
+2.77% | 15.28B | B+ | ||
-9.25% | 15.18B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- ROSSARI Stock
- Ratings Rossari Biotech Limited